The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

authors:

avatar Nasser Ebrahimi Daryani 1 , * , avatar Babak Haghpanah 2 , avatar Ali Reza Sayyah 2 , avatar Ali Asad Hashtroudi 2 , avatar Mohammad Bashashati 2 , avatar Parisa Poursamimi 2 , avatar Mehri Nikbin 2

Tehran University of Medical Sciences, Imam Khomeini Hospital & Study Group of Interferon in Iran (SG.IFN.IR), nebrahim@sina.tums.ac.ir, Tehran, IR.Iran
Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, IR.Iran
Hepatitis Monthly: Vol.4, issue 7; 71-74
article type: Research Article

how to cite: Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7): 71-74. 

Abstract

Background and aims: Peginterferon alpha-2a is a known standard therapy for patients with chronic HCV infection. However efficacy and safety of this treatment is still unclear in regional settings. This study was designed to clarify efficacy and safety of peg-interferon based therapy in Iranian patients.
Methods: 23 patients were treated with Peginterferon alpha-2a in combination with ribavirin for 48 weeks. The patients were observed for adverse effects and response to therapy during treatment and 24 weeks after the end of therapy.
Results: Early virologic response, end of treatment response, and sustained virologic response rates were 86.9 % (20/23), 82.6 % (19/23), and 78.3 % (18/23) respectively. The most common adverse effects in descending order were flue-like symptoms (74%), mood changes (48%), and weight loss (43%). 
Conclusion: Combination therapy with Peginterferon alpha-2a and ribavirin for 48 weeks is an effective treatment with minimal adverse effects.

Full Text

Full text is available in PDF